Using a combination of in vitro stem cell assays and in vivo murine models, this is the first study to robustly report efficacy for a SMO inhibitor, as a single agent, or in combination with a TKI, in models of CP-CML. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.